Literature DB >> 12492611

Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

Michiel J B Kemme1, Jacobus Burggraaf, Rik C Schoemaker, Cornelis Kluft, Adam F Cohen.   

Abstract

AIMS: Heparin releases tissue factor pathway inhibitor (TFPI) from the endothelium and this release may decrease after repeated high dose heparin administration. The primary aim was to investigate and quantify this phenomenon during a short low dose heparin infusion. Also, the effects of heparin on tissue plasminogen activator (t-PA) were studied.
METHODS: Nine healthy, nonsmoking, male volunteers (range 19-23 years) received a continuous heparin infusion (2000 IU) over 40 min. The endothelial TFPI release rate was estimated from the total TFPI concentration profile using a pharmacokinetic model.
RESULTS: Mean +/- s.d. total and free TFPI increased from 62.9 +/- 9.4/8.3 +/- 2.1 ng ml-1 at baseline to 237.2 +/- 40.9/111.0 +/- 19.9 ng ml-1 after 40 min infusion. The relationship between heparin concentration (anti-IIa activity) and TFPI concentration followed a maximum effect model and a clockwise loop (proteresis) was observed. The TFPI release rate rapidly increased to maximum of 200 +/- 45 micro g min-1 after 17.5 min heparin infusion but did not increase further although heparin concentrations further doubled. In contrast to TFPI, t-PA antigen decreased from 5.6 +/- 1.0 at baseline to 4.5 +/- 1.0 ng ml-1 at the end of infusion (t = 40 min) (difference of 1.1 ng ml-1 (95% confidence interval; 0.9, 1.3).
CONCLUSIONS: Our application of concentration-effect models and pharmacokinetic principles to these haemostatic variables showed that endothelial TFPI release has a maximum that is already reached at low heparin dose, corresponding with an anti-IIa activity of 0.08 IU ml-1. The relationship between anti-IIa activity and TFPI release rate showed signs of acute tolerance (clockwise loop) indicating exhaustion of endothelial TFPI pools. These findings may be of importance for the heparin dose used in conditions such as unstable angina, in which the favourable effects of heparin have been ascribed to its ability to release TFPI.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12492611      PMCID: PMC1874485          DOI: 10.1046/j.1365-2125.2002.t01-1-01705.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Repeated release of the tissue factor pathway inhibitor.

Authors:  R A Ariëns; E M Faioni; P M Mannucci
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

2.  Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.

Authors:  R Wesselschmidt; K Likert; T Girard; T C Wun; G J Broze
Journal:  Blood       Date:  1992-04-15       Impact factor: 22.113

3.  Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.

Authors:  R Wesselschmidt; K Likert; Z Huang; L MacPhail; G J Broze
Journal:  Blood Coagul Fibrinolysis       Date:  1993-10       Impact factor: 1.276

4.  Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

Authors:  S Valentin; O Nordfang; C Bregengård; P Wildgoose
Journal:  Blood Coagul Fibrinolysis       Date:  1993-10       Impact factor: 1.276

5.  The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.

Authors:  D A Hoppensteadt; W Jeske; J Fareed; E W Bermes
Journal:  Blood Coagul Fibrinolysis       Date:  1995-06       Impact factor: 1.276

6.  The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.

Authors:  I Warshawsky; G Bu; A Mast; J E Saffitz; G J Broze; A L Schwartz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.

Authors:  P Théroux; D Waters; S Qiu; J McCans; P de Guise; M Juneau
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

8.  Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits.

Authors:  C Bregengaard; O Nordfang; P Ostergaard; J G Petersen; G Meyn; V Diness; O Svendsen; U Hedner
Journal:  Thromb Haemost       Date:  1993-09-01       Impact factor: 5.249

Review 9.  The present status of tissue factor pathway inhibitor.

Authors:  A K Lindahl; P M Sandset; U Abildgaard
Journal:  Blood Coagul Fibrinolysis       Date:  1992-08       Impact factor: 1.276

10.  Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions.

Authors:  D A Hoppensteadt; W Jeske; J Fareed; A N Nicolaides
Journal:  Int Angiol       Date:  1996-03       Impact factor: 2.789

View more
  8 in total

1.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

2.  Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

Authors:  Qing Ma; Mahmut Tobu; Christopher Schultz; Walter Jeske; Debra Hoppensteadt; Jeanine Walenga; Umberto Cornelli; John Lee; Robert Linhardt; Israel Hanin; Jawed Fareed
Journal:  Thromb Res       Date:  2006-07-07       Impact factor: 3.944

3.  A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor.

Authors:  Offer Erez; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Francesca Gotsch; Juan Pedro Kusanovic; Nandor Gabor Than; Shali Mazaki-Tovi; Edi Vaisbuch; Zoltan Papp; Bo Hyun Yoon; Yu Mi Han; Debra Hoppensteadt; Jawed Fareed; Sonia S Hassan; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2008-10

4.  Tissue factor and its natural inhibitor in pre-eclampsia and SGA.

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Nandor Gabor Than; Jawed Fareed; Shali Mazaki-Tovi; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Sung-Su Kim; Bo Hyun Yoon; Sonia S Hassan; Francesca Gotsch; Lara Friel; Edi Vaisbuch; Juan Pedro Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2008-12

5.  Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial.

Authors:  Mauro Panigada; Elena Spinelli; Alberto Cucino; Elisa Cipriani; Stefano De Falco; Giovanna Panarello; Giovanna Occhipinti; Antonio Arcadipane; Gabriele Sales; Vito Fanelli; Luca Brazzi; Cristina Novembrino; Dario Consonni; Antonio Pesenti; Giacomo Grasselli
Journal:  Trials       Date:  2019-06-11       Impact factor: 2.279

6.  Fibrin Strands Will Grow from Soluble Fibrin and Hang Up in an In Vitro Microcirculatory Viscoelastic Model: Is This a Major Cause of COVID-19 Associated Coagulopathy?

Authors:  Brian S Bull; Karen L Hay; Paul C Herrmann
Journal:  J Clin Med       Date:  2022-04-07       Impact factor: 4.964

7.  A macrophage attack culminating in microthromboses characterizes COVID 19 pneumonia.

Authors:  Brian S Bull; Karen L Hay
Journal:  Immun Inflamm Dis       Date:  2021-07-07

8.  Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.

Authors:  Osheiza Abdulmalik; Noureldien H E Darwish; Vandhana Muralidharan-Chari; Maii Abu Taleb; Shaker A Mousa
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.